SethKarolMDMSCI(He/Him)
Pediatric Hematology & Oncology • Memphis, TNAssociate Member- Leukemia/ Lymphoma Division St. Jude Children's Research Hospital
Dr. Karol is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105
Summary
- Dr. Seth Karol is a pediatric hematologist/oncologist in Memphis, TN and is affiliated with St. Jude Children's Research Hospital. He received his medical degree from The Ohio State University College of Medicine and has been in practice as a pediatric oncologist since 2012. He has expertise in experienced acute lymphoblastic leukemia, acute myeloid leukemia, treatment side effects, early phase clinical trials, and pharmacogenomics.
Education & Training
University of TennesseeFellowship, Pediatric Hematology/Oncology, 2012 - 2015
Case Western Reserve Univ/Univ Hosps Cleveland Med Ctr/Rainbow Babies and Childrens HospitalResidency, Pediatrics, 2008 - 2011
Ohio State University College of MedicineClass of 2008
Certifications & Licensure
TN State Medical License 2012 - 2025
OH State Medical License 2008 - 2012- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase Start of enrollment: 2020 Sep 04
- Hypertension Intervention to Reduce Osteonecrosis in Children With Acute Lymphoblastic Leukemia/Lymphoma Start of enrollment: 2020 Oct 15
- Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) Start of enrollment: 2022 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- Molecular and pharmacological heterogeneity of ETV6::RUNX1 acute lymphoblastic leukemia.Zhenhua Li, Huanbin Zhao, Wenjian Yang, Maud Maillard, Satoshi Yoshimura
Nature Communications. 2025-01-29 - Novel classification system and high-risk categories of pediatric acute myeloid leukemia.Masayuki Umeda, Yen-Chun Liu, Seth E Karol, Jeffery M Klco
Haematologica. 2025-01-09 - 1 citationsOutcomes in patients with ETV6::RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studies.Katelyn Purvis, Yinmei Zhou, Seth E Karol, Jeffrey E Rubnitz, Raul C Ribeiro
Blood. 2025-01-09
Lectures
- Safety and activity of venetoclax in combination with high-dose cytarabine in children with relapsed or refractory acute myeloid leukemia.ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
- Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Press Mentions
Venetoclax plus High-Dose Cytarabine with or Without Idarubicin Well Tolerated in Pediatric AMLMay 1st, 2020
ASH Annual Meeting Highlights St. Jude ResearchDecember 6th, 2019
Venetoclax Combo Therapy Shows Promise in Pediatric Patients with R/R AMLJune 14th, 2019- Join now to see all
External Links
- St. Jude profilehttp://www.stjude.org/karol
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
